Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Cancer risk not increased by anti-TNF therapy

Cancer risk is not increased during the first six years after starting anti-tumour necrosis factor (anti-TNF) alpha treatment in patients with rheumatoid arthritis (RA), a new study indicates (Arthritis & Rheumatism 2009;60:3180).

Researchers based in Sweden examined the short- and medium-term cancer risk for 6,366 patients using infliximab, adalimumab or etanercept, comparing the incidence of new cancers diagnosed among these patients with other groups of RA patients (see Panel).

The researchers found that the relative risk of developing cancer did not increase or decrease with increasing time since the start of anti-TNF therapy, nor did it increase with the cumulative duration of active anti-TNF therapy.

When considering the three anti-TNF therapies separately, none was associated with an increased overall risk of cancer. However, differing risks were observed during the first year of follow-up (users of etanercept had a lower cancer risk than those RA patients who were anti-TNF naive, whereas adalimumab users were at an increased risk).

The researchers state: “The effect of an anti-TNF agent on cancers seen during an early stage of therapy might be due to existing preclinical tumours becoming clinically manifest, either by allowing more actual tumour growth or by influencing the development of clinical symptoms as a result of the presence of the cancer, rather than being due to the occurrence of a new cancer.”

They add that patients receiving anti-TNF therapy have a cancer risk similar to RA patients who have not received such therapy, patients starting methotrexate and patients starting with a nonbiological disease-modifying antirheumatic drug combination therapy.

Study details and findings

Data for 6,366 patients receiving anti-TNF therapy, followed for the equivalent of 25,693 person-years, were compared with those for 61,660 anti-TNF naive RA patients (330,498 person-years), 5,989 patients starting methotrexate therapy (23,558 person-years) and 1,838 patients starting non-biological disease-modifying antirheumatic drugs (DMARD) combination therapy (7,043 person-years).

The relative risk (RR) of a first primary cancer occurring in the anti-TNF group (240 cancers) compared with an anti-TNF naive RA patient (4,244 cancers) was 1.00 (95 per cent confidence interval 0.87–1.17).

This risk did not change with increasing duration of anti-TNF therapy (RR 0.96, CI 0.50–1.86, for those with six years or more anti-TNF therapy).

The RR compared with the methotrexate group, where 260 cancers occurred, was 0.99 (CI 0.79–1.24).

The RR compared with the DMARD group, where 64 cancers occurred, was 0.97 (CI 0.69–1.36).

Citation: The Pharmaceutical Journal URI: 10984630

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £54.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Rheumatoid arthritis patient

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.